The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures-Reference-Cited by-全球学者库

The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures

Published:2016-02-22 Issue:12 Volume:7 Page:15033-15046
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Lin Ziying¹²³,Xu Yutong¹²³,Zhang Yaxiong¹²³⁴,He Qihua¹²,Zhang Jianrong¹²,He Jianxing¹²,Liang Wenhua¹²

Affiliation:

1. Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

2. Guangzhou Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou, China

3. Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China

4. Department of Medical Oncology of Sun Yat-sen University Cancer Center, Guangzhou, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stereotactic Body Radiotherapy and Immunotherapy for Older Patients with Oligometastases: A Proposed Paradigm by the International Geriatric Radiotherapy Group;Cancers;2022-12-30

2. Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer;Human Antibodies;2022-08-26

3. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer;Annals of Oncology;2021-03

4. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis;Frontiers in Oncology;2021-02-01

Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC

;OncoTargets and Therapy;2020-11